Effect of ambrisentan, bosentan and macitentan on human hepatic uptake and efflux transporters

H. Gillies, I. Lepist, J. Hao, A. Ray (Foster City, United States Of America)

Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Session: Pulmonary circulation: clinical PAH, registries and treatments
Session type: Thematic Poster Session
Number: 952

Congress or journal article abstract

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
H. Gillies, I. Lepist, J. Hao, A. Ray (Foster City, United States Of America). Effect of ambrisentan, bosentan and macitentan on human hepatic uptake and efflux transporters. Eur Respir J 2012; 40: Suppl. 56, 952

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Intracellular accumulation and effects on bile acid transport of endothelin receptor antagonists in sandwich-cultured hepatocytes
Source: Annual Congress 2013 –Pulmonary circulation: clinical science and treatment
Year: 2013

Effect of CYP3A4 inhibitors verapamil and itraconazole on the pharmacokinetics of AZD7986, an oral DPP1 inhibitor
Source: International Congress 2017 – Asthma management
Year: 2017


Superior in vivo efficacy of macitentan: Comparison to other endothelin receptor antagonists
Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments
Year: 2012

Lack of relevant pharmacokinetic interactions between the new dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012


Optimization of tissue targeting properties of macitentan, a new dual endothelin receptor antagonist, improves its efficacy in a rat model of pulmonary fibrosis associated with pulmonary arterial hypertension
Source: Annual Congress 2011 - Treatment of human pulmonary hypertension
Year: 2011


Lack of relevant pharmacokinetic and pharmacodynamic interactions between the new dual endothelin receptor antagonist macitentan and warfarin in healthy subjects
Source: Annual Congress 2012 - Pulmonary circulation: clinical PAH, registries and treatments
Year: 2012


Change of sildenafil plasma concentrations after transition from bosentan to macitentan in pulmonary arterial hypertension
Source: International Congress 2016 – Pulmonary hypertension: the clinic II
Year: 2016

Effect of dexfenfluramine on the development of pulmonary hypertension in mice over-expressing the serotonin transporter
Source: Eur Respir J 2005; 26: Suppl. 49, 352s
Year: 2005

Effects of steady-state female hormones on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide
Source: Annual Congress 2011 - Drug delivery and pharmacokinetics II
Year: 2011


Blockage of serotonin receptors and transporter reduces bleomycin lung fibrosis in mice
Source: Eur Respir J 2005; 26: Suppl. 49, 82s
Year: 2005

Effect of the CYP3A4 inhibitor ketoconazole on the pharmacokinetics and pharmacodynamics of AZD5069, an oral CXCR2 antagonist
Source: International Congress 2014 – Novel evidence relating to respiratory treatment development
Year: 2014

The victim potential of sitaxentan: metabolism by human CYP450 enzymes
Source: Annual Congress 2008 - Pulmonary vascular disease and other pulmonary conditions: miscellaneous
Year: 2008


The absorption, distribution, metabolism and excretion (ADME) of single oral doses of AZD5069, a novel CXCR2 antagonist, in healthy male volunteers
Source: Annual Congress 2012 - The best of pharmacology treatments of airway diseases: new devices and drugs
Year: 2012

Safety and pharmacokinetics of aclidinium bromide, a novel, long-acting muscarinic antagonist, in renally impaired subjects
Source: Annual Congress 2009 - Next generation bronchodilators
Year: 2009


Comparison of inhibitory potentials of pranlukast and zafirlukast on human liver CYP isoforms
Source: Eur Respir J 2003; 22: Suppl. 45, 102s
Year: 2003

Impact of co-administration of fevipiprant (QAW039) and SLCO1B1 genotype on the PK of simvastatin and rosuvastatin
Source: International Congress 2016 – Pharmacological intervention in humans and murine models of asthma
Year: 2016

The uptake of ciclesonide-active metabolite and budesonide into human hepatocytes in vitro – the effect of serum protein binding
Source: Eur Respir J 2006; 28: Suppl. 50, 434s
Year: 2006

Effects of steady-state enoxacin on single-dose pharmacokinetics of roflumilast and roflumilast N-oxide
Source: Annual Congress 2009 - New bronchodilators
Year: 2009


Sustained efficacy with the selective endothelin-A receptor antagonist, sitaxsentan, after two years of therapy in patients with pulmonary arterial hypertension
Source: Eur Respir J 2005; 26: Suppl. 49, 204s
Year: 2005

Effects of bosentan, ambrisentan and TBC3711 on TNFα induced and endothelin-1 modulated gm-csf expression in human airway smooth muscle cells
Source: Annual Congress 2009 - Airway cell biology
Year: 2009